News - Ipsen, Merck KGaA

Filter

Current filters:

IpsenMerck KGaA

Popular Filters

1 to 25 of 155 results

Merck Serono in deal with Auxogyn to advance fertility research

03-04-2014

USA-based Auxogyn, a company dedicated to advancing women’s reproductive health, has entered into an…

AuxogynLicensingMerck KGaAMerck SeronoPharmaceuticalReproductive

EMD Serono, Pfizer and Broad Institute link up on lupus research

EMD Serono, Pfizer and Broad Institute link up on lupus research

01-04-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA, has signed a research agreement with US pharma…

Anti-Arthritics/RheumaticsEMD SeronoMerck KGaAPfizerPharmaceuticalResearch

Merck promotes internal top managers to head Merck Millipore and Consumer Health Divisions

Merck promotes internal top managers to head Merck Millipore and Consumer Health Divisions

26-03-2014

German pharma and chemical major Merck KGaA has announced the promotion of three distinguished internal…

AllergopharmaBiotechnologyBoardroomGermanyMerck KGaAPharmaceutical

Germany’s Merck benefits from efficiency measures, with 2013 EBITDA up 9.7%

Germany’s Merck benefits from efficiency measures, with 2013 EBITDA up 9.7%

06-03-2014

German pharma and chemical major Merck KGaA this morning announced strong fourth-quarter and full-year…

FinancialMerck KGaAMerck SeronoPharmaceutical

Ipsen returns to profit, with drug sales up 2.1%

28-02-2014

Full-year 2013 group revenues at French drugmaker Ipsen came in at 1.28 billion euros ($17.59 billion),…

FinancialIpsenPharmaceutical

Merck Serono’s Erbitux to be funded by CDF in England for mCRC

28-02-2014

The UK’s Cancer Drugs Fund (CDF) says that Erbitux (cetuximab) can be used in the first line setting…

ErbituxFinancialHealthcareMerck KGaAMerck SeronoNorthern EuropeOncologyPharmaceuticalUK

Merck names Simon Sturge as new head of biosimilars unit

Merck names Simon Sturge as new head of biosimilars unit

20-02-2014

Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding…

BiosimilarsBiotechnologyBoardroomManagementMerck KGaA

Ipsen posts top results for Phase III study of Decapeptyl in prostate cancer

Ipsen posts top results for Phase III study of Decapeptyl in prostate cancer

07-02-2014

French drugmaker Ipsen has announced that the Phase III clinical trial evaluating Decapeptyl (triptorelin…

DecapeptylFranceIpsenOncologyPharmaceuticalResearch

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

05-02-2014

French drugmaker Ipsen today announced the results of the international Phase III clinical trial of Dysport…

DysportFranceGeneticsIpsenPharmaceuticalResearch

Merck KGaA names new board members

Merck KGaA names new board members

28-01-2014

E. Merck KG, which combines the financial interests of the Merck family and is general partner of Germany’s…

BoardroomGermanyMerck KGaAPharmaceutical

Ipsen’s sales grow 2.2% in 2013, but miss expectations

Ipsen’s sales grow 2.2% in 2013, but miss expectations

28-01-2014

French drugmaker Ipsen posted solid sales growth for fourth-quarter and full-year 2013, though there…

FinancialIpsenPharmaceutical

Ipsen, a good European mid-cap to watch, says US analyst

Ipsen, a good European mid-cap to watch, says US analyst

27-01-2014

Most American investors are familiar with large European drugmakers like Sanofi and Novartis but the…

FinancialIpsenOncologyPharmaceuticalResearchSomatulinetasquinimod

Merck KGaA’s CFO Matthias Zachert joins Lanxess as CEO

Merck KGaA’s CFO Matthias Zachert joins Lanxess as CEO

27-01-2014

Chief financial officer of Germany’s Merck KGaA (MRK: DE) Matthias Zachert has been appointed as chief…

BoardroomLanxessMerck KGaAPharmaceutical

Ipsen implements new US governance to prepare for Somatuline launch in oncology

Ipsen implements new US governance to prepare for Somatuline launch in oncology

22-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced new governance in the USA following its decision…

BoardroomIpsenOncologyPharmaceuticalSomatulineUSA

Ipsen reveals positive results for Somatuline

Ipsen reveals positive results for Somatuline

17-01-2014

French drugmaker Ipsen (Euronext: IPN) has announced that Somatuline Autogel/Somatuline Depot (lanreotide)…

FranceIpsenOncologyPharmaceuticalResearchSomatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

14-01-2014

French drugmaker Ipsen (Euronext: IPN) and UK-based GW Pharmaceuticals (Nasdaq: GWPH) have entered into…

FranceGW PharmaceuticalsIpsenLicensingPharmaceuticalSativexSomatuline

Ipsen recruits executive VP, technical operations

Ipsen recruits executive VP, technical operations

10-01-2014

French drugmaker Ipsen has appointed Jonathan Barnsley as executive vice president in charge of technical…

BoardroomIpsenManagementPharmaceutical

European Commission backs wider use of Merck’s Erbitux

European Commission backs wider use of Merck’s Erbitux

24-12-2013

Merck Serono, the biopharmaceutical division of Germany’s Merck KGaA, has gained European Commission…

ErbituxEuropeMerck KGaAMerck SeronoOncologyPharmaceuticalRegulation

Merck Serono partners with Spanish research center for cancer drug development

Merck Serono partners with Spanish research center for cancer drug development

19-12-2013

Merck Serono, the biotech division of German life sciences group Merck KGaA, has signed an accord with…

BiotechnologyLicensingMerck KGaAMerck SeronoNorthern EuropeOncologyResearch

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

Dominique Brard joins Ipsen as Executive Vice President of Human Resources

19-12-2013

French pharmaceutical company Ipsen has announced the appointment of Dominique Brard as Executive Vice…

BoardroomEuropeIpsenNeurologicalOncologyPharmaceutical

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

Ipsen reports positive Phase III results for Dysport in adult upper limb spasticity

17-12-2013

French drugmaker Ipsen (Euronext: IPN) has announced positive initial results from a Phase III study…

DysportIpsenNeurologicalNorthern EuropePharmaceuticalResearch

Merck’s Allergopharma to invest 40 million euros in production facility

Merck’s Allergopharma to invest 40 million euros in production facility

12-12-2013

Germany’s Merck KGaA has broken ground on a new production facility for its Allergopharma unit in Reinbek…

AllergopharmaFinancialImmunologicalsMerck KGaAPharmaceuticalProduction

1 to 25 of 155 results

Back to top